Figure 3.

Evaluation of the anti-tumor effects of murine iPSCs derived from BALB/c or C57BL/6 mice. (A) Evaluation of the anti-tumor effects of C57BL/6- derived miPSCs murine with or without VPA. Eight to 10 weeks old female BALB/c mice, were divided into 4 groups: group control (PBS; n = 7), mice treated with VPA (n = 8) or miPSCs alone (n = 8), and mice treated with miPSCs + VPA (n = 8). Treatment consisted of two sub-cutaneous injections (one-week interval between injections) of 2 × 10⁶. One week following the second injection, all mice were inoculated with 5 × 10⁴ 4T1Luc cells into mammary fat-pad following by 21 days of VPA treatment, orally administered at dose of 4 mg/mL. (B) Representative bioluminescence imaging of tumors from mice treated with miPSCs, VPA and miPCs+VPA compared to untreated mice. (C) Tumor growth in 8–10 weeks old, BALB/c mice that were immunized with murine C57BL/6-derived iPSCs; with (n = 5) or without VPA (n = 5), compared to control group (n = 5) by using the same protocol as previously. (D) Tumor growth in 8–10 weeks old, BALB/c mice that were immunized with murine BALB/c-derived iPSCs; with (n = 5) or without VPA (n = 5), compared to control group (n = 5) by using the same protocol as previously. (E) Effect of allogeneic C57BL/6-derived miPSC treatment on the survival of mice BALB/c challenged with 5 × 10⁴ 4T1 cells (n=5 per group). (F) Effect of autologous BALB/c-derived miPSC treatment on the survival of BALB/c mice challenged with 4T1 cells 5 × 10⁴ 4T1 cells (n=5 per group). (G) Effect of allogeneic C57BL/6-derived miPSC +VPA treatment on the survival of mice BALB/c challenged with 5 × 10⁴ 4T1 cells (n = 5 per group). (H) Effect of autologous BALB/c-derived miPSC treatment on the survival of BALB/c mice challenged with 4T1 cells 5 × 10⁴ 4T1 cells (n = 5 per group). ** p < 0.01, *** p < 0.001.